oral tirzepatide dosing for weight loss Tirzepatide: Availability, Alternatives, and More Microdosing Tirzepatide Chart: A Weekly

If these findings are sustained beyond 3 months and validated in the randomized cohort, this could become a viable solution for the many patients who would like to stop GLP-1 medications but currently cant. The study is an open-label cohort trial aimed at evaluating the safety, tolerability, and early efficacy of Revita for patients who lost at least 15% or more of their total body weight with a recently discontinued GLP-1

PMID: 41529878

Nakamura Y, Tsuji M, Hasegawa H, Kimura K, Fujita K, Inoue M, et al

Assessment of nuclear transfer techniques to prevent the transmission of heritable mitochondrial disorders without compromising embryonic development competence in mice